Targeting the Proteostasis Network for Mycobacterial Drug Discovery | Zendy

Tania J. Lupoli | Zendy; Julien Vaubourgeix | Zendy; Kristin Burns-Huang | Zendy; Ben Gold | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Targeting the Proteostasis Network for Mycobacterial Drug Discovery

Author(s) -

Tania J. Lupoli,

Julien Vaubourgeix,

Kristin Burns-Huang,

Ben Gold

Publication year - 2018

Publication title -

acs infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.324

H-Index - 39

ISSN - 2373-8227

DOI - 10.1021/acsinfecdis.7b00231

Subject(s) - proteostasis , mycobacterium tuberculosis , tuberculosis , proteome , biology , drug discovery , proteasome , proteases , drug , immunity , microbiology and biotechnology , antibiotics , immunology , medicine , bioinformatics , immune system , pharmacology , genetics , biochemistry , pathology , enzyme

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains one of the world's deadliest infectious diseases and urgently requires new antibiotics to treat drug-resistant strains and to decrease the duration of therapy. During infection, Mtb encounters numerous stresses associated with host immunity, including hypoxia, reactive oxygen and nitrogen species, mild acidity, nutrient starvation, and metal sequestration and intoxication. The Mtb proteostasis network, composed of chaperones, proteases, and a eukaryotic-like proteasome, provides protection from stresses and chemistries of host immunity by maintaining the integrity of the mycobacterial proteome. In this Review, we explore the proteostasis network as a noncanonical target for antibacterial drug discovery.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research